Company intelligence / Profile preview

Emiota

Durham, North Carolina, United Statestheverge.com ↗

Ownership: Private
Development stage: Commercial

Overview

EmitBio has developed the RD-X19™, a drug-free, light-based medical device targeting the oropharynx to treat and reduce symptoms of respiratory infections. The technology has advanced through preclinical and clinical safety studies and reached pivotal trials for mild COVID‑19. Early results suggest potential to speed recovery, reduce viral load, and lessen disease severity[1].

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: DeviceLight-based therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Emiota.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emiota.

Explore the full profile